The role and efficacy of Opicapone and evaluation of actual patient efficacy

Opicapone is an oral peripheral selective catechol-O-methyltransferase (COMT) inhibitor, mainly used for patients with Parkinson's disease (PD) accompanied by "on-off" fluctuations. Its mechanism of action is to inhibit the peripheral metabolism of dopamine, thereby extending the half-life of levodopa (L-DOPA), increasing dopamine levels in the brain, and helping to improve motor symptoms, especially reducing "off" time and movement fluctuations.

In clinical studies, Opicapone has shown clear efficacy advantages. Multiple clinical trials have shown that Opicapone significantly increases daily "on" time while reducing "off" time compared to placebo. For patients taking levodopa/carbidopa combination therapy but still experiencing motor fluctuations, adding opicapone can improve daytime mobility and quality of life. Its long-term efficacy has also been verified to some extent. After patients continued to use it for several weeks to several months, the stability of their motor control was significantly enhanced.

Actual feedback from patients shows that Opicapone has a significant effect in improving movement fluctuations. Most patients report that the "on" time is increased, their exercise ability is more stable, and their daily activities are less restricted. Since the drug is a once-daily oral dose, it is more convenient to take and patient compliance is generally good. Some patients may experience mild side effects, such as constipation or mild insomnia, but overall it is well tolerated.
It should be noted that Opicapone cannot cure Parkinson's disease, nor can it reverse neuron loss. Its effect is mainly reflected in symptom management and improvement of motor stability. Therefore, patients should use opicapone in combination with levodopa and other anti-Parkinson drugs under the guidance of a neurologist, and regularly evaluate the efficacy and adverse reactions to achieve the best individualized treatment effect.
Reference link: https://www.drugs.com